Please use this identifier to cite or link to this item: http://www.repositorio.cdtn.br:8080/jspui/handle/123456789/1274
Title: Saccharomyces cerevisiae UFMG A-905 treatment reduces intestinal damage in a murine model of irinotecan-induced mucositis
Title of periodic: Beneficial Microbes
Authors: Bastos, Rafael Wesley
Pedroso, Silvia Helena Sousa Pietra
Vieira, Angélica Thomáz
Moreira, Luciana M.C.
França, Cassandra S.
Cartelle, Christiane Teixeira
Arantes, Rosa Maria Esteves
Generoso, Simone Vasconcelos
Cardoso, Valbert Nascimento
Neves, Maria José
Nicoli, Jacques Robert
Martins, Flaviano Dos Santos
Affiliation: Universidade Federal de Minas Gerais, UFMG, Belo Horizonte, MG, Brasil
Universidade Federal de Minas Gerais, UFMG, Belo Horizonte, MG, Brasil
Universidade Federal de Minas Gerais, UFMG, Belo Horizonte, MG, Brasil
Universidade Federal de Minas Gerais, UFMG, Belo Horizonte, MG, Brasil
Universidade Federal de Minas Gerais, UFMG, Belo Horizonte, MG, Brasil
Universidade Federal de Minas Gerais, UFMG, Belo Horizonte, MG, Brasil
Universidade Federal de Minas Gerais, UFMG, Belo Horizonte, MG, Brasil
Universidade Federal de Minas Gerais, UFMG, Belo Horizonte, MG, Brasil
Universidade Federal de Minas Gerais, UFMG, Belo Horizonte, MG, Brasil
Centro de Desenvolvimento da Tecnologia Nuclear, CDTN, Belo Horizonte, MG, Brasil
Universidade Federal de Minas Gerais, UFMG, Belo Horizonte, MG, Brasil
Universidade Federal de Minas Gerais, UFMG, Belo Horizonte, MG, Brasil
Issue Date: 2016
Keywords: Saccharomyces cerevisiae;Oxidative stress;Yeast;Probiotic agent
Abstract: Indigenous microbiota plays a crucial role in the development of several intestinal diseases, including mucositis. Gastrointestinal mucositis is a major and serious side effect of cancer therapy, and there is no effective therapy for this clinical condition. However, some probiotics have been shown to attenuate such conditions. To evaluate the effects of Saccharomyces cerevisiae UFMG A-905 (Sc-905), a potential probiotic yeast, we investigated whether pre- or post-treatment with viable or inactivated Sc-905 could prevent weight loss and intestinal lesions, and maintain integrity of the mucosal barrier in a mucositis model induced by irinotecan in mice. Only post-treatment with viable Sc-905 was able to protect mice against the damage caused by chemotherapy, reducing the weight loss, increase of intestinal permeability and jejunal lesions (villous shortening). Besides, this treatment reduced oxidative stress, prevented the decrease of goblet cells and stimulated the replication of cells in the intestinal crypts of mice with experimental mucositis. In conclusion, Sc-905 protects animals against irinotecan-induced mucositis when administered as a post-treatment with viable cells, and this effect seems to be related with the reduction of oxidative stress and preservation of intestinal mucosa.
Access: R
Appears in Collections:Artigo de periódico

Files in This Item:
File Description SizeFormat 
Saccharomyces cerevisiae UFMG A-905 treatment reduces intestinal damage.pdf641.34 kBAdobe PDFView/Open    Request a copy


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.